Alyson Justice
Primary Care · Huntsville, ALNPI 1396204905
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 40.6% of the total.
Across 95 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$697
- Astellas Pharma US Inc$395
- GSK$111
- Bayer$59
- AstraZeneca$53
- Merck$47
- plus $356 from 12 others
What the payments were for
- Food & beverage$1,61894%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 37 | $697 |
| Astellas Pharma US Inc | 21 | $395 |
| GSK | 6 | $111 |
| Bayer | 3 | $59 |
| AstraZeneca | 4 | $53 |
| Merck | 3 | $47 |
| AbbVie | 2 | $46 |
| Lilly USA, LLC | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Novo Nordisk | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Urovant Sciences Inc | 1 | $22 |
| Insulet Corporation | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Axonics, Inc. | 1 | $15 |
How this compares
$1,718 in reported general payments places this provider in the 65th percentile of 159 primary care providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 314 | $259,291 |
| GemtesaVibegron | 219 | $181,175 |
| Estradiol | 459 | $75,159 |
| ElmironPentosan Polysulfate Sodium | 32 | $38,215 |
| Mirabegron ErMirabegron | 22 | $16,605 |
| Tolterodine Tartrate ErTolterodine Tartrate | 111 | $14,905 |
| LinzessLinaclotide | 20 | $14,379 |
| YuvafemEstradiol | 80 | $13,806 |
| EstringEstradiol | 17 | $9,210 |
| Methenamine Hippurate | 71 | $7,778 |
| Solifenacin Succinate | 128 | $5,770 |
| Doxycycline Hyclate | 61 | $1,750 |
| Clobetasol Propionate | 50 | $1,747 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $1,666 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $395 | $259,291314 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $697 | $181,175219 claims |
| AbbVieLinzess | $46 | $14,37920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 159 primary care providers in Alabama.
Other primary care in Huntsville
- Cleo ValdezHuntsville$14K
- Christine WoodHuntsville$5K
- Allison BrownHuntsville$4K
- Meredith PolsHuntsville$3K
- Emory ColemanHuntsville$3K
- Emily KomaraHuntsville$2K
- Johnnie AmadiHuntsville$2K
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.